NCT00365183 - Trial of Motexafin Gadolinium and Pemetrexed (Alimta®) for Second Line Treatment in Patients With Non-Small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

January 31, 2008

Study Completion Date

June 30, 2008

Conditions

Non-Small Cell Lung Carcinoma

Interventions

DRUG

Motexafin gadolinium and pemetrexed

1 dose of MGd 15 mg/kg and pemetrexed 500 mg/m2 once during the first week of every 3-week treatment cycle for a maximum of 12 cycles

Trial Locations (11)

Huntington Beach

Long Beach

Chicago

Baltimore

Minneapolis

St Louis

Albuquerque

Santa Fe

Armonk

Columbus

Seattle